YH-003 (HUMANIZED AGONISTIC ANTI-CD40 IGG2 MONOCLONAL ANTIBODY)
Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltdmonoclonal_antibodyPhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 59/ 100
Competitive context
1411 Active assets in the Advanced Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nabiximols Jazz Pharmaceuticals | Phase 3 | BBB |
Inno-206 M.D. Anderson Cancer Center | Phase 2 | BB |
Vitamin B6 M.D. Anderson Cancer Center | Phase 4 | BB |
PROPOFOL Hong Kong Children's Hospital | Phase 4 | BB |
Rivoceranib Jiangsu HengRui Medicine Co., Ltd. | Phase 4 | BB |
View all 50 →
Same molecule, other indications
YH-003 (HUMANIZED AGONISTIC ANTI-CD40 IGG2 MONOCLONAL ANTIBODY) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →